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GLOSSARY1 
 
 
 
Health-related quality of life (HRQoL): A combination of a person's physical, mental and 
social well-being; not merely the absence of disease. 
 
 
HRQoL weights: Measure of the preference or value that an individual or society places 
upon a particular health state. It is generally a number between zero (representing death) and 
1 (perfect health).  
 
 
National health services (NHS) costs/perspective: Costs and outcomes relating to hospital 
and primary care services and prescribed medications. 
 
 
NO2:  Nitrogen dioxide. 
 
 
NOx:  Oxides of nitrogen, comprises Nitrogen dioxide (NO2) and nitric oxide (NO) 
 
 
Personal social services (PSS) costs/perspective: Care services for vulnerable people, 
including those with special needs because of old age or physical disability that fall outside 
the remit of the NHS. Examples include residential care homes for the elderly, home help and 
home care services, and social workers who provide help and support for a wide range of 
people.  
 
 
PM2.5:  0DVVFRQFHQWUDWLRQRISDUWLFOHVRIJHQHUDOO\OHVVWKDQȝPDHURG\QDPLFGLDPHWHU
Often referred to as fine particles, this fraction can penetrate deep into the lungs. 
 
 
PM10: Mass FRQFHQWUDWLRQRISDUWLFOHVRIJHQHUDOO\ OHVV WKDQȝPDHURG\QDPLFGLDPHWHU
This fraction can enter the lungs. PM10 includes PM2.5. 
 
 
Quality-adjusted life year (QALYs): A measure of the state of health of a person in which 
the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is 
equal to 1 year of life in perfect health.  
 
 
Willingness to pay (WTP): The amount an individual is willing to pay to acquire some good 
or service.  For non-traded goods, WTP may be elicited from stated or revealed preference 
approaches. 
 
  
                                                        
1 Based on definitions provided by NICE; Department of Health and DEFRA. 
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Executive summary 
 
 
This toolkit is targeted at local authorities in the UK. It aims to generate estimates of QALY 
losses and health care costs (NHS and PSS) per tonne of emission of PM2.5 and NOx (or 
NO2) emitted, in order to support the economic evaluation of air quality measures. As a 
number of inputs were derived from the Leeds-Bradford Low Emission Zone (LEZ) feasibility 
study, the toolkit is especially appropriate for the economic evaluation of air quality measures 
in this region, using information on the targeted population size and the expected annual 
reduction in pollutant load (spread-VKHHW³XVLQJHPLVVLRQGDWDRQO\´. Alternatively, in order to 
evaluate air quality measures outside of West Yorkshire or in areas with a substantial 
different population density than Leeds/Bradford, it is possible to enter area-specific estimates 
of avoided cases of adverse health endpoints as input data of the toolkit (via spread-sheet 
³8VLQJHPLVVLRQVDQG+,$UHVXOWV´ 
 
The approach to toolkit development is detailed in sections 2 and 3 of the main report. In a 
first stage, the annual health effects per tonne emission reduction were computed based on 
information on estimated emissions changes and modeled reduction in concentrations for the 
Leeds-Bradford LEZ feasibility study. By contrasting the scope of analysis chosen for Leeds-
Bradford LEZ study with HIA guidelines and evidence assessments from institutions in the 
UK, EU, and US and re-conducting the health impact assessment, the present work updated 
the study performed by Cooper at al. (2014). In a second stage, the QALY and health care 
costs impact associated with each endpoint was calculated by extending the work produced 
by Lomas et al. (2015) and modifying some structural assumptions. 
 
All the explanations pertaining to the use of the toolkit including input data to enter (such as 
money value for a QALY, target population size, emission reduction) is provided in the 
spread-VKHHW ³5($'-0(´ RI WKH WRRONLW A great strength of the toolkit is to allow a certain 
level of customization, so that it matches more closely with the end-XVHU¶V QHHGV and/or 
remains up-to date with the latest epidemiological evidence and guidelines. More specifically, 
the end-user can: 
(i) Alter the VHOHFWLRQ RI KHDOWK HQGSRLQWV FRQVWLWXWLQJ ³ORZ´ DQG ³KLJK´ UDQJHV of 
impacts 
(ii) Incorporate the latest epidemiological evidence for a particular endpoint, or 
guidance pertaining to adjustment for co-pollutant effect, by adjusting estimates 
of numbers of averted cases of this endpoint /tonne /year/ 100,000 individuals.  
=>The formulas for adjustment are provided in section 4 of the report. 
(iii) Enter area-specific estimates of avoided cases of adverse health endpoints as 
input data. The latter would need to be calculated separately by linking changes 
in emissions to change in concentrations and associated health effects. 
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1. Background  
 
1.1. Toolkit objective and final users  
 
The objective of this toolkit is to generate estimates of QALY losses and health care costs 
(NHS and PSS) per tonne of emission of PM2.5 and NOx (or NO2) emitted, in order to 
support the economic evaluation of air quality measures. This toolkit is targeted at local 
authorities in the UK. 
 
A number of inputs of the toolkit were derived from a study in Yorkshire (Leeds-Bradford Low 
Emission Zone ³/(=´ feasibility study). Consequently the toolkit is especially appropriate for 
the economic evaluation of air quality measures in this region. However, in order to support 
the use of this toolkit across local authorities, two forms of analysis were allowed: 
- One level: spread-VKHHW³using emission data RQO\´is all automated and simply requires the 
size of the target population and the expected annual reduction in pollutant load (tonnes of 
PM2.5 and NOx or NO2) as input data.  
- Alternatively, for a more precise estimation of QALY gains and health care resource savings 
associated with air quality measures to be implemented outside of West Yorkshire or in areas 
with a substantial different population density than Leeds/Bradford, it is possible to enter 
area-specific estimates of avoided cases of adverse health endpoints in the spread-sheet 
³8VLQJ HPLVVLRQV DQG +,$ UHVXOWV´. These estimates are obtained by linking changes in 
emissions to changes in concentrations and associated health effects. 
 
The present toolkit focuses on the health effects from chronic exposure to fine particulate 
matter (PM2.5) and nitrogen dioxide (NO2). Whilst NO2 concentrations will be the unit of 
reference when discussing epidemiological findings, since NOx emissions are the precursor 
to NO2 concentrations, the computation of QALY and costs impacts will typically be based on 
the change in NOx emissions. In the toolkit, the end-user can enter a reduction (or an 
increase) in either NOx or NO2  emissions by appropriately choosing the ratio of NO2 / NOx in 
WKH³XVHULQSXWGDWD´VSUHDGVKHHW 
 
1.2. Differences with '()5$¶VGDPDJHFRVW approach 
 
This approach represents DQ DOWHUQDWLYH WR '()5$¶V GDPDJH FRVWV approach, which is 
currently prevailing in the UK (DEFRA, 2013, 2015) for proposals of impacts below £50 
million. The differences are threefold: 
 
Firstly, this approach places a much stronger emphasis on the chronic morbidity effects of air 
pollution exposure and their associated quality of life loss, which thus far have been largely 
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ignored. Indeed, the morbidity effects currently considered by DEFRA are currently restricted 
to cardio-respiratory hospital admissions following acute exposure to particulate pollution 
(DEFRA, 2013, 2015). By contrast, the present approach considers the loss of quality of life 
from the development of chronic cardio-respiratory conditions and, in sensitivity analysis, 
prematurity.  
 
Secondly, the identification of the endpoints to include in the scope of analysis was not solely 
based on current guidelines for the UK, but was also informed by recommendations and 
evidence assessments in the EU and US. Additionally, the choice of epidemiological evidence 
to inform the selected endpoints was informed by current guidelines as well as thorough 
searches on specialized databases.  
 
Thirdly, whilst the DEFRA approach uses a social cost benefit perspective by monetizing 
health endpoints via willingness to pay (WTP), this approach instead focuses on the NHS 
perspective. It considers healthcare costs incurred by the NHS and personal social services 
(PSS) alongside health impacts. By using the QALY as health metric, this approach supports 
the comparison between the cost-effectiveness of air quality measures with health care 
interventions, which are commonly assessed in terms of cost/QALY gained. However, in 
FRQWUDVWZLWK'()5$¶VRII-the-shelf damage costs, the toolkit allows the end-user to enter the 
money value for a QALY. Therefore, depending on the perspective of analysis chosen, the 
value of a QALY to the NHS, or alternatively to the taxpayer, may be used. In practice, the 
value of £20,000/QALY is typically used as a reference for the value of health to the NHS 
(NICE, 2013) whereas, from the WD[SD\HU¶V perspective, the Department of Health (Glover 
and Henderson, 2010) recommends to use a WTP value for a QALY of £60,000/QALY (in 
2009 prices). 
 
Fourth, instead of providing an overall damage cost result, a strength of this toolkit is to allow 
the end-user to: (i) understand the contribution of each health endpoint to the final result, (ii) 
customise the scope of analysis (beyond the choice of money value for a QALY) and (iii) 
easily update the toolkit input data as further epidemiological evidence is released or as 
guidelines are updated (see section 4). 
 
1.3. Method outline 
 
The present work builds upon: 
(1) A health impact assessment (HIA) carried out as part of the Leeds-Bradford Low Emission 
Zone (LEZ) feasibility study (Cooper et al., 2014);  
(2) Estimates of QALY gain and health care resource saving per adverse health outcome 
included in the above HIA from Lomas et al. (2015) 
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To ensure that the input parameters of the present toolkit were sound and most up-to date, 
these two components were re-analysed and sensitivity analysis were performed.  
 
The first stage consisted of computing annual health effects per tonne emission reduction, 
based on information on estimated emissions changes and modeled reduction in 
concentrations for the Leeds-Bradford LEZ feasibility study. By contrasting the scope of 
analysis chosen for Leeds-Bradford LEZ HIA with HIA guidelines and evidence assessments 
from institutions in the UK, EU, and US and re-conducting the health impact assessment, the 
present work updated the study performed by Cooper at al. (2014). This will be discussed in 
section 2.  
 
The second stage consisted of building on the work produced by Lomas et al. (2015) with 
regards to QALY loss and health care costs associated with each adverse health endpoints. 
To populate the toolkit, the analysis was extended and some of the structural assumptions 
underpinning QALY and costs computations were modified.  
 
 
2. Computation of health effects per tonne emission reduction 
 
 
This section outlines any updated methodology and input data compared to the HIA 
conducted by Cooper et al. (2014), in order to obtain estimates of health impacts per tonne 
emission reduction. 
 
 
2.1. Health impact function 
 
In addition to expanding the scope of analysis and using most up to date evidence, the 
present work applies alternative methods to generate health impacts.  
 
The change in health effects associated with the expected change in pollutants 
concentrations was computed using the standard log-linear health impact function, as 
opposed to the formula of attributable fraction used in Duncan et al (2014), which is instead 
relevant for computing the burden of ill health attributable to a given level of exposure.  
 
Indeed most epidemiological studies use a log-linear statistical model (e.g. Cox proportional 
KD]DUGWRPRGHOWKHLQFLGHQFHUDWHRIHQGSRLQW³\´IRUDLUSROOXWLRQ³[´VXFKWKDW 
ORJ\ ȕ[ORJĮZKHUH 
- ȕLVWKHVORSHFRHIILFLHQWRIWKHFRQFHQWUDWLRQUHVSRQVHIXQFWLRQDQG 
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- ĮLVWKHEDVHOLQHLQFLGHQFHUDWH RIHQGSRLQWXQGHUQRSROOXWLRQĮZLOOLWVHOIEHDIXQFWLRQRI
many covariates impacting endpoint incidence).  
7KH FKDQJH LQ QXPEHU RI FDVHV RI KHDOWK HQGSRLQW \ ǻ\ DVVRFLDWHG ZLWK D FKDQJH LQ
SROOXWLRQFRQFHQWUDWLRQ[ǻ[FDQWKHUHIRUHEHH[SUHVVHGDV:  
 
ǻ\ \0 >H[Sȕǻ[- 1] * pop   
 
where: 
-  H[Sȕǻ[HTXDOV WR WKH ULVNHVWLPDWH 5(ǻ[)  UHSRUWHGE\ HSLGHPLRORJLFDO VWXGLHV ZLWKǻ[
EHLQJW\SLFDOO\HTXDOWRRUȝJP3 . 
-  y0 is the baseline incidence rate  of endpoint y. 
- pop is the size of the population targeted by the change in exposure. Typically y0 will be 
expressed per 1000 or 100,000 individuals so the parameter pop should be rescaled 
accordingly. 
 
In line with the above  -  and in contrast with the approach used by Duncan et al (2014) which 
used linear scaling -  risk estimates from epidemiological studies  (REǻ[)  were scaled to the 
modeled change in concentrations associated with the intervention under assessment ǻP
using log multiplicative scaling, such that:  
REǻP  = x = REǻ[ ǻPǻ[ 
 
The health impact function used to compute the expected change in number of cases of 
endpoint y (ǻ\, attributable to the change in concentrations obtained from dispersion 
PRGHOOLQJǻPPD\WKHUHIRUHEHH[SUHVVHGDV 
 
 
ǻ\>ǻP@  = y0 [REǻ[   ǻPǻ[ - 1] * pop         (1) 
 
 
 
2.2. Identification of relevant health endpoints and epidemiological evidence  
 
2.2.1. Analysis scope: 
 
It should be underlined that the present scope of analysis only focuses on chronic health 
impacts associated with long-term exposure. In other words, acute effects associated with 
pollution episodes are not presently taken into account in the analysis. The reason for this is 
driven by the input data for the toolkit. It is populated by annual change in emissions and its 
impact on mean annual concentrations, as opposed to daily concentrations. The focus on 
chronic health effects associated with long-term exposure is unlikely to substantially 
 9 
underestimate the benefit associated with emission reduction since: (i) the life expectancy 
effects of acute exposure are included in the excess mortality risk from long-term exposure 
(Kunzli et al., 2001) and (ii) acute effects are not expected to significantly contribute towards 
quality of life effects. 
 
 
2.2.2. Comparative analysis of &RRSHU HW DO ¶V HIA with current guidelines and past 
evidence assessments: 
 
As explained in section 1.3, the HIA conducted for Leeds-Bradford low emission zone (LEZ) 
by Cooper et al. (2014) was the starting point of the current work. In populating the toolkit, this 
HIA was updated in order to ensure that this key input data would reflect the latest evidence 
and guidelines and used appropriate methodology. 
 
More specifically, for each endpoint included in the HIA, two questions were evaluated: 
Q1) Is there an adequate justification for endpoint inclusion in analysis? 
Q2) Should the source of epidemiological evidence be updated and/or should the effect size 
be adjusted to account for pollutant overlap? 
 
Question Q1 was informed by compDULQJWKHVFRSHRI&RRSHUHWDO¶V+,$DJDLQVWWKH
latest guidelines for HIA of air pollution control interventions and evidence assessments from 
institutions in the UK, EU and the US, namely: 
- COMEAP: Committee of Medical Effects of Air Pollutants (COMEAP, 2010, 2015),  
- WHO - HRAPIE group: Health Risks of Air Pollution In Europe (WHO, 2013) 
- US EPA. For the US EPA, both the approach followed in its latest Regulatory Impact 
Analysis for the Proposed Revisions to the National Ambient Air Quality Standards for 
Particulate Matter (US EPA, 2012a) and Integrated Science Assessments (ISA) for 
respectively PM (US EPA 2009, 2012b) and NO2 (US EPA 2015) were used to inform the 
comparative analysis with Cooper et al. (2014).  
 
Question Q2 was informed by reviewing the above institutions¶ guidelines and evidence 
assessments and also by performing thorough literature searches for latest epidemiological 
results for each endpoint using PubMed and Ludok databases. A summary of the evaluation 
undertaken to answer Q1 and Q2 is reported in Appendix A. In addition, the strength of 
evidence for widening the scope of endpoints, whilst accounting for the risk of double 
counting, was evaluated. The conclusions of this assessment are provided in Appendix B. 
In comparing the HIA conducted for Leeds-Bradford LEZ against current guidelines and 
evidence assessments and results from literature searches in specialized databases, the 
following modifications were made to the HIA:   
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1- Epidemiological evidence was updated for the following endpoints: 
- All cause mortality; 
- Childhood asthma; 
- Low birth weight of term birth. 
 
2- Two endpoints were added to the scope of chronic adverse impacts for either main or 
sensitivity analysis:  
 
(i) Incidence of chronic bronchitis in adults associated with PM exposure; 
Parameterisation of the excess risk of developing chronic bronchitis in adults will rely on the 
risk estimate recommended by the HRAPIE group (WHO 2013) which results from the polling 
of two estimates from a study in the US (Abbey et al., 1995) and another in Switzerland 
(Schindler et al. 2009). 
 
(ii) All cause mortality associated with NO2 exposure. 
Since the toolkit is to be used in assessments of air quality measures in the UK, the excess 
risk of mortality associated with chronic exposure to NO2 ZLOOEHLQIRUPHGE\&20($3¶VODWHVW
interim JXLGDQFH&20($3 ,W LVKRZHYHUZRUWKXQGHUOLQLQJWKDW&20($3¶V current 
recommended estimate to quantify the link between long-term exposure to NO2 and all-cause 
mortality (1.025  with 95% CI = 1.01-1.04 for ǻNO2    ȝJP3) appears conservative in 
comparison to past results from two meta-analyses studies. Indeed Hoek et al. (2013) and 
Faustini et al. (2014) reported pooled effect estimates of respectively 1.055 (95% CI = 1.031, 
1.08) and 1.04 (95% CI =1.02±SHUȝJPLQFUHPHQWLQDQQXDODYHUDJHNO2. 
 
3- In line with COMEAP (2015) and WHO (2013) recommendations, risk estimates for health 
endpoints associated with both PM2.5 and NO2 exposure were adjusted to account for effect 
overlap between both pollutants. For mortality effects, in line with HRAPIE guidelines (WHO, 
2013)2, COMEAP recommends to reduce NO2 concentration-response coefficients by up to 
one third and, in order to obtain a central estimate, to reduce effect sizes by half this range, 
i.e. by 1/6th. Therefore, in the cases where the air quality measure under evaluation would 
reduce both NOx (NO2) and PM emissions, a reduction by 1/6th was applied to the estimates 
linking NO2 exposure with the excess risk of all-cause mortality and low birth weight term 
births3 (see Table 4). 
 
                                                        
2 This (0 ± 33)% reduction range was suggested by the HRAPIE group (WHO 2013) since results from 
multi-pollutants models could not provide a precise estimation of the size of overlap, whereby some 
multi-pollutants models yielded effect size greater than results without adjustment for co-pollutants.  
 
3
 In the toolkit, an adjustment factor of 1.20 is therefore applied to numbers of averted cases pertaining 
to these two endpoints if the policy under assessment is expected to only reduce NOx (NO2) emissions. 
For these two endpoints, the value of 1.2 indeed represents a very close approximation of the true 
adjustment factor: AFNO2  5(ǻ[± 5(ǻ[(1 ± 1/6) - 1), (see section 4.2.). 
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4- Adverse endpoints associated with PM2.5 exposure were classified in two ranges. The 
³ORZ UDQJH´FRPSULVHVHQGSRLQWV IRUZKLFKFXUUHQWHYLGHQce strongly supports a causal link 
with exposure: namely all-FDXVH PRUWDOLW\ DQG FRURQDU\ HYHQWV 7KH  ³KLJK UDQJH´
complements these two endpoints with endpoints that are currently recommended to be 
considered in sensitivity analysis as the epidemiological evidence supporting them is slightly 
weaker - i.e. suggests, rather than indicates, a causal relationship ± namely: adverse birth 
outcomes and incidence of chronic bronchitis in adults.  
 
5- By contrast, the computation of a ³high´ versus ³low´ range of adverse effects associated 
with NOx emissions was not performed. Indeed, whilst the evidence of low birth weight 
associated with NOx is suggestive rather than indicative of a causal relationship, this endpoint 
was found to have a limited contribution to the overall net benefit from NOx emission 
reduction. Consequently, the creation of two ranges of impacts based solely on the 
inclusion/exclusion of this endpoint was not deemed necessary.  
 
Table 1 presents the endpoints considered for each pollutant and each range of effect. It also 
highlights the difference in scope and epidemiological evidence used in comparison with the 
HIA conducted by Cooper et al. (2014). 
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Evidence 
update (% 
diff in mean 
effect) 
Source 
Risk estimate 
(REǻ[) and 95%CI 
ǻ[ = ȝJP3 
Endpoint 
Low 
range 
High 
range 
PM2.5 
All cause 
Death 
x x Yes (0%) 1 Hoek et al.  
2013 
1.06 (1.04 - 1.08) 
CHD cases 
 
x x No Cesaroni et al. 2014 2 1.41 (1.00 - 2.01) 
Chronic 
Bronchitis 
 
Newly 
added 
N.A 
WHO 2013 (for 
PM10) 3 1.12 (1.04 - 1.19) 
Term LBW 
 
 x Yes (-73%) Dadvand et al. 2013 1.10 (1.03 - 1.18) 
Pre Term 
Birth 
 x No 
Sapkota et al.  
2012 
1.15 (1.14 - 1.16) 
Endpoint 
Base  
case 
NO2 
All cause 
Death  
Newly added N.A COMEAP 2015 4 1.025 (1.01 - 1.04) 
Childhood 
asthma (prev.) x Yes (-14%) Favarato et al. 2014 1.06 (1.00 - 1.11) 
Term LBW 
 
x No 
Pedersen et al.  
2013 4 
1.09 (1.00 - 1.19) 
 
Table 1: Health endpoints and risk estimates for health impact computations 
 
1 Hoek et al. (2013) pooled estimate has a smaller variance than the effect estimate from Pope et al 
(2002) but mean estimates are the same between both studies. 
 
2 Cesaroni et al. (2014) reported effect estimatHV IRU ǻPM2.5   ȝJP 1.19 (1.00 - 1.42). Results 
KDYHEHHQFRQYHUWHGKHUHIRUǻPM2.5  ȝJPIRUpresentational coherence.
  
 
3 In line with WHO (2013), the effect size from this study will be multiplied by a factor of 1.54 to provide 
the equivalent impact per unit of PM2.5. 
 
4 As explained in section 2.2.2, these original estimates were reduced by 1/6th (middle value of the 0-
33% range) when populating the toolkit, in order to account for overlap in effect between PM and NO2.   
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2.3. Baseline health data  
 
2.3.1. Mortality:  
 
Directly age-standardised rates (DSR) that are obtained by combined age- specific event 
rates observed in the study population with the relative frequencies of age groups within a 
standard population (European Standard Population), were used for background mortality 
incidence. Whilst it may be argued that for health impact assessment, crude event rates - i.e. 
number of events per total at risk population - is preferable, this choice was driven by an effort 
to ensure data consistency between endpoints and districts. Indeed for Bradford and for 
hospitalizations data, only DSR for the total all age population were available. DSR were 
obtained based on the last 3 to 5 years of available crude data.  
 
2.3.2. Low birth weight:  
 
Baseline data on low birth weight was modified in order to account only for term births who 
were of low weight (<2500 kg), in order to avoid double counting with the health endpoint: 
pre-term birth which is also considered in the analysis. Data on term low birth weight, as of 
2012, was obtained from the Public health outcome framework for each district. Considering 
only low weight births that are at term halved the baseline incidence rate used for health 
impact computations (4.5% and 3.1% of all births in Bradford and Leeds as opposed to 
respectively 9.1% and 7.2% of all births in Bradford and Leeds when considering all low birth 
weight births). 
 
2.3.3. Pre-term birth:  
 
As the source of data on prematurity used in the previous HIA could not be reliably 
reproduced, the latest available estimates on prematurity from England and Wales were used 
(7.3% of births as at 2012, ONS 2013). 
 
2.3.4. Coronary event: 
 
The background data used to model the change in numbers of coronary events was restricted 
to CHD hospitalizations (I20:I25) only, as opposed to hospitalizations for all CVD causes 
(ICD10: I00- I199) as was done in Cooper et al. (2014). This choice is justified by the need to 
be coherent with the final endpoint chosen (i.e. cases of coronary events) as well as the 
epidemiological evidence used in the health impact function (Cesaroni et al. 2014). Like for 
mortality data, DSR of hospitalizations for the entire population was used.  
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The obtained results in terms of avoided CHD cases is obviously lower when using CHD 
hospitalizations, as opposed to CVD hospitalizations, to inform the baseline incidence rate of 
coronary events.  Indeed in 2011, CHD hospitalizations represented about 29% of all CVD 
hospitalizations in England (Towsend et al., 2012). 
 
In addition, the analysis was extended by including the change in incidence of coronary event 
in Leeds since the past HIA (Cooper et al., 2014) only included computations for Bradford. 
CHD hospitalizations rate in Leeds are publicly available at MSOA level from the West 
Yorkshire Observatory. 
 
2.3.5. Chronic bronchitis: 
 
Since chronic bronchitis is part of the disease group: chronic obstructive pulmonary disease 
(COPD), there is sparse population statistics collected on the incidence of chronic bronchitis 
only. In addition it was not possible to get hold of data on COPD incidence (only prevalence 
data was available in Leeds). In the absence of adequate information on the background 
incidence rate of chronic bronchitis, WHO (2013) recommends to use the incidence rate 
measured in the SAPALDIA study (Schindler et al., 2009) 4 . Therefore, the background 
incidence rate used for the present computation is: 3.9 cases / 1,000 individuals aged 19 and 
above. 
 
2.3.6. Childhood asthma: 
 
For this endpoint, the same background data was used as in Cooper et al. (2014). Data on 
childhood (0-18 yrs old) asthma prevalence was collected in Leeds in 2014, as part of a 
regular health audit of the population. For Bradford, estimates of asthma prevalence in 
children were available at district level only.  
 
3.3.7. Summary of spatial resolution of baseline health data for each endpoint: 
 
Table 2 shows the spatial resolution of the baseline health data corresponding to each 
endpoint included in the analysis. District level signifies Leeds or Bradford overall.  
                                                        
4
 This study was also used to inform the excess risk of developing chronic bronchitis due to PM 
exposure see section 2.2.2. 
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Table 2: Spatial resolution of baseline health data for each endpoint. 
 
 
2.4. Pollution concentration data 
 
Pollution concentrations data by LSOA was provided by Leeds city council. A previous 
mismatch between concentrations and emission data for Bradford was corrected by using the 
most up to date figures. 
 
2.5. Computation of avoided cases per tonne of pollutant emission reduction  
 
Computation of estimates of health effects per tonne emission reduction require health 
impacts associated with a given decrement in concentrations to be linked with the level of 
emissions reduction that is expected to drive such a concentration change. This was done 
XVLQJWKHVFHQDULRCC$OOSUH(852EXVHVDQG+*9VXSJUDGHGWR(852E\´WREH
implemented in Outer Ring Roads (ORR) of Leeds Bradford.  
 
 
Endpoint 
 
 
Spatial resolution 
 
 
Source 
 
All cause 
mortality 
 
- Bradford: LSOA 
- Leeds: LSOA 
 
- Bradford city council  
- Leeds city council 
 
CHD incidence 
 
- Bradford: LSOA 
- Leeds: MSOA 
 
- Bradford city council  
- Leeds: West Yorkshire observatory 
(http://observatory.leeds.gov.uk/dataviews/) 
 
Chronic bronchitis 
 
Bradford & Leeds: district 
level (using estimates for 
Switzerland as proxy) 
 
WHO (2013) (using estimates from  
Schindler et al., 2009) 
 
Term birth low birth 
weight 
 
- Bradford: District level 
- Leeds: District level 
 
Public health outcome framework 
(http:// http://www.phoutcomes.info/) 
 
Pre-term birth 
 
Bradford & Leeds: district 
level (using national 
estimates for England and 
Wales as proxy) 
Office for National Statistics (2013) 
 
Asthma prevalence 
(0-18 yrs old) 
 
- Bradford: district level 
- Leeds: LSOA  
 
- Bradford city council 
- Leeds asthma audit 2014.  
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Table 5 reports the expected change in annual emissions and the corresponding decrement 
in population-weighted concentrations for respectively Leeds and Bradford Outer Ring Roads 
areas associated with this scenario. Emissions data was reported in Appendix 1 - Tables A6, 
A7, A14, A15 of Cooper et al. (2014). It is worth noting that in line with Cooper et al. (2014), it 
was assumed that only 50% of NOx concentrations is of NO2 (the pollutant for which 
epidemiological evidence is based). 
 
 
 
 
Leeds (ORR area) 
 
Bradford (ORR area) 
 
Population (all ages) 375,082 79,124 
 
ǻ30emissions/year 11.6 1.9 
 
ǻ pop-weighted 30FRQFLQȝJP3 0.57 0.08 
 
ǻ12[emissions/year 290 62.3 
 
ǻSRS-ZHLJKWHG12[FRQFLQȝJP3 5.23 0.62 
 
ǻSRS-weighted NO2 FRQFLQȝJP3    1 2.62 0.31 
 
1 Assuming 50% of NOx concentrations is NO2. 
 
Conc. = concentration (LQȝJP3ǻ ³FKDQJHLQ´ 
 
 
Table 3: Reduction in annual PM2.5 and NOx emissions, and corresponding decrements in 
population-weighted concentrations in Leeds and Bradford Outer Ring Roads areas, 
associated with the scenario ``All pre EURO 4 buses and HGVs upgraded to EURO 6 by 
´ 
 
 
 
Health impact assessment was computed separately for Leeds and Bradford. The health 
impact function (equation 1, section 2.1.) was applied to compute the numbers of avoided 
cases of each selected endpoint associated with PM2.5 and/or NOx exposure, whilst 
adjusting for overlap in effect between both pollutants (see section 2.2.2).  
 
Whilst concentration data was available at LSOA level, as underlined in Table 2, the 
background rate of incidence of adverse endpoints considered in the analysis was available 
at three different administrative levels, namely: LSOA, MSOA or district. The change in 
avoided cases was therefore computed using population-weighted concentration data 
corresponding to the spatial scale for which baseline health data was available.  Results 
computed at a finer spatial scale than district-level were then aggregated to provide an 
estimate for Leeds and Bradford respectively.  
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Table 6 reports the total annual numbers of avoided cases of each endpoint for Leeds and 
Bradford ORR areas. Importantly with regards to children asthma, the health impacts pertain 
to a change in prevalence as opposed to incidence and the intervention effect is therefore not 
annual. Figures in brackets represent the lower and upper bound values based on the 95% 
confidence intervals of epidemiological risk estimates.  
 
 
 
Pollutant 
 
Endpoint 
 
Leeds (ORR area) 
 
Bradford (ORR area) 
 
PM 
 
All-cause Death 8.4   (5.7 - 11.1) 0.3    (0.2 - 0.35) 
 
CHD cases 20.5  (0 - 41.7) 2.8    (0.0 - 5.56) 
 
Chronic bronchitis 10.9  (3.9 - 17.1) 0.26  (0.09 - 0.40) 
 
Term LBW 0.9    (0.3 - 1.5) 0.04  (0.01 - 0.07) 
 
Pre Term Birth 3.0    (2.8 - 3.2) 0.10  (0.09 - 0.10) 
 
NO2 
 
All-cause Death 13.6   (5.5 - 21.7) 0.4    (0.15 - 0.60) 
 
Childhood asthma (prev.) 1 117.7 (0 - 212.0) 3.7    (0 - 6.60) 
 
Term LBW 3.0     (0 - 6.1) 0.12  (0 - 0.25) 
 
1 One-off impact.  
 
Table 4: Expected change in numbers of adverse cases per year associated with ``All pre 
(852EXVHVDQG+*9VDUHXSJUDGHGWR(852E\´ 
 
 
 
These results were combined with data on emission and targeted population size presented 
in Table 3 to generate the total number of cases averted /tonne emission reduction /year/ 
100,000 inds (all ages). 
 
Results for Leeds and Bradford were then combined using a population-weighted approach 
(Leeds pop-weight = 83%; Bradford pop-weight = 17%, see population numbers in Table3) in order to 
populate the toolkit with a single set of estimates for each endpoint. For childhood asthma, 
only results for Leeds were used since the baseline health data was available at a much more 
refined scale than for Bradford (see Table 2). 
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3. Linking averted cases with QALY and NHS and PSS cost impacts 
 
 
This step relied on the work produced by Lomas et al. (2015) but implemented some 
modifications with regards to the structural assumptions underpinning QALY and health care 
resource use computations. In addition, since /RPDVHWDO ¶VZRUNZDVSHUIRUPHGIRU
the endpoints considered in the HIA conducted by Cooper et al. (2014), i.e. not including 
chronic bronchitis, QALY losses and health care costs associated with this endpoint were 
calculated. A summary of the differences between the present computations and those of 
Lomas et al. (2015) may be found in Appendix C. 
 
 
3.1. General framework  
 
A QALY is computed by multiplying the time spent in a given health condition with the health-
related quality of life (HRQoL) associated with that state of health (Gold et al., 2001). It 
follows that the QALY loss associated with each case of chronic disease x may be expressed 
as the sum of two elements A+ B where: 
$UHSUHVHQWVWKHTXDOLW\RI OLIH ORVVRFFXUULQJRYHU WKH LQGLYLGXDO¶VUHPDLQLQJ OLIHH[SHFWDQF\ 
conditional on having disease x; 
B represents the life year loss associated with disease, scaled to the counterfactual HRQoL 
RI³KHDOWK\´LQGLYLGXDOVLHZLWKRXWGLVHDVHx). 
 
Denoting: 
- DLEi,x and DLEi,h the discounted remaining life expectancy of individuals of age i if 
respectively with disease x or if healthy; 
- HRQoLi,x and HRQoLi,h the HRQoL scores for individuals of age i if respectively with 
disease or healthy  
 
We can express A and B as: 
A= DLEi,x (HRQoLi,h - HRQoLi,x)  
B= HRQoLi,h (DLEi,h  - DLEi,x)  
 
It is worth underlining that element B is expected to be captured in the overall loss of life 
expectancy that is informed by the risk estimates of excess mortality from all causes. It 
follows that, when all-cause mortality is also considered as a health endpoint, to avoid 
double-counting of life expectancy gains, the QALY loss from each case of disease x should 
be based on element A only.  
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3.2. Method 
 
Computation of QALY gain - and by extension health care resource savings - associated with 
a reduction in cases of morbidity and mortality following air pollution decrement required to 
characterise four components. Each component will be described in the sections 3.2.1. to 
2.2.4 and summarised in Table 5. 
 
3.2.1. Timing of disease development / adverse event occurrence 
 
Since age-specific morbidity and mortality data was unavailable, the numbers of (avoided) 
cases of each endpoint were computed for the total all-age population targeted by the air 
quality measure (see section 2). Characterisation of the timing of adverse event was therefore 
based on the average age of the population subgroup assumed to be at risk of experiencing 
adverse health events5.  
 
At-risk subgroups were defined as: 45 years old and above for CHD and chronic bronchitis; 0-
18 years old for asthma and 75 years old and above for premature death. Data on age-
specific life expectancy and statistics on age and gender population distribution required to 
compute the average age of individuals in at-risk subgroups was based on the population of 
England and Wales, to support the generalizability of the toolkit outside of West Yorkshire. 
Importantly, the use of population statistics for England and Wales, as opposed to Leeds and 
Bradford, had a minimal impact on final results. 
 
3.2.2. The reduction in life expectancy associated with each adverse morbid event 
 
The reduction in life expectancy associated with CHD was computed by applying hazard 
ratios of excess death provided by Whiteley et al. (2005) to the baseline mortality rates of 
individuals of the general population who do not suffer from CHD, that were obtained from 
life-table computation using ONS data (ONS, 2014). CHD was found to reduce life 
expectancy by 3.4 years for males at age 62 and 2.6 years for females at age 63. When 
compared with individuals of the general population (which include both individuals with and 
without CHD), suffering from CHD was associated with a 2-year reduction in life expectancy 
for both genders.  
 
For prematurity, the reduction in life expectancy was computed based on the excess risk of 
suffering from a disability (Mangham et al. 2009). By contrast, chronic bronchitis and asthma 
were assumed to have no impact on life expectancy and the reduction. 
                                                        
5
 Importantly, this is not necessarily the same as the population subgroup for which the change in 
incidence was computed. For instance, whilst the change in numbers of CHD cases was computed 
using directly age-standardised rates for the total all-age population, it is well known that young 
individuals are very unlikely to suffer from coronary events. 
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3.2.3. The duration of the disease  
 
As shown in equation A, if the disease is chronic, as is the case of CHD, chronic bronchitis, 
the duration is simply the remaining life expectancy at time of event. For childhood asthma, it 
was assumed that the disease would continue into adulthood with a 58% probability (Oswald 
et al., 1994). 
 
3.2.4. The health-related quality of life (HRQoL) weight associated with each condition. 
 
For mortality, the HRQoL of individuals of the general population of England (Kind et al., 
2009) aged above 75 were used as counterfactual for quality of life. For morbid conditions, 
age-constant decrement in HRQoL (i.e. HRQoLi,h - HRQoLi,x) estimated by Sullivan et al. 
(2011) were used.  
 
For CHD, decrements were provided for specific heart conditions (i.e. acute myocardial 
infarction, old myocardial infarction, angina pectoris and other chronic ischemic heart 
disease). To obtain an overall result for this disease, a weighted average of these decrements 
was computed based on hospitalizations statistics by causes of heart disease for England 
and Wales (Townsend et al., 2012). Additionally, in order to account for the fact that the loss 
of quality of life after a myocardial infarction is expected to be partially regained in the 
following months after the event, two CHD-related HRQoL decrements were computed for 
respectively (i) the year of event onset and (ii) subsequent years.  
 
3.2.5. Summary of assumptions underpinning each four components 
 
 
The assumptions pertaining to each four components underpinning QALY and health care 
costs impacts computations for each adverse health endpoint are presented in Table 5.
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Endpoint 1 - Timing of event 2- Life expectancy impact/person  3- Duration  4- HRQoL 
All-cause mortality After age 75 LE loss = 2 years 2 N.A. 
Used counterfactual HRQoL score for 
the general population of England aged 
75+ from Kind et al. (1999): 
HRQoL75,h  =0.73 
CHD incidence 
 
After age 45  
(mean age: 62 for males, 63 
for females) 
See section 2.3.2.2. 
DLEi,x  = DLEi,h - 2 
From onset until death 
(brought forward) 
Weighted HRQoL decrement  
(see section 2.3.2.2.) 
Yr1: HRQoLi,h - HRQoLi,x  = -0.0688  
Yr2: HRQoLi,h - HRQoLi, x = -0.0627 
Chronic bronchitis 
 
After age 45  
(mean age: 62 for males, 63 
for females) 
No life-shortening, i.e. 
DLEi,x  = DLEi,h From onset until death 
HRQoL decrement from  
Sullivan et al (2011):  
HRQoLi,h - HRQoLi,x  = -0.0444 
Term birth low birth 
weight 
 
N.A. Only health care costs were attributed to this endpoint 
Pre-term birth (PTB) 
 
At birth 
Depending on level of 
disability:11 years of life loss 
for moderate disability and 
53 life years loss for severe 
disability 
For those suffering from a 
disability due to PTB, a 
lifetime impact was 
assumed  
HRQoL associated with each disability 
level from Colbourn et al. (2007) 1 
 
N.B. Computation of QALY loss (and health care costs) associated with PTB, were underpinned by differences in risk of being born 
with a disability using the disability rates of term birth as counterfactual. Data was obtained from Mangham et al (2009) 1 
 
Asthma prevalence 
(0-18 yrs old) 
At 10 years old which is the 
mean age of England and 
Wales population aged 0-18  
No life-shortening, i.e. 
DLEi,x  = DLEi,h 
From onset until 18 years 
old with a 58% probability 
(Oswald et al., 1994) 1 that 
the disease will continue in 
adulthood until death 
HRQoL decrement from Sullivan et al 
(2011) 
HRQoLi,h - HRQoLi,x  = -0.0463 
 
1
 Study sourced from Lomas et al (2015).   
2
 Sensitivity checks assuming that individuals dying prematurely from air pollution exposure would loose on average 1 year (as opposed to 2 years) of life expectancy barely 
impacted on results (8.6 QALY loss as opposed to 8.4 in base case). 
i represents the average age at which event are assumed to occur; h represent individuals of the general population of age i; x stands for the morbid endpoints considered: 
chronic bronchitis, CHD, asthma. 
 
Table 5: Assumptions underpinning QALY and health care cost impacts computation. 
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3.3. Costs data sources.  
 
Costs were computed based on the same data sources as Lomas et al (2015). For chronic 
bronchitis, which was added to the scope of relevant endpoints, the costs was based on 
available evidence for COPD. 
 
In the UK, the department of health produced an estimate of annual cost of COPD of £ 810 
million for about 800,000 patients as at 2009 (DH, 2010), which is equivalent to an annual 
cost of £1,102 per COPD patient in 2014 prices. However, COPD includes emphysema which 
is a more severe condition and the health care costs associated with the disease strongly 
depends on the level of advancement of the disease, i.e. degree of airflow obstruction.  
Therefore, the costs of stage 2 COPD estimated for Sweden by Jansson et al. (2013) was 
instead selected as a proxy for the cost of chronic bronchitis in the present analysis. When 
converted into GBP and inflated to 2014 prices, stage 2 was associated with an annual cost 
of £955/patient. 
  
 
3.4. QALY and health care costs impacts estimates 
 
 
Table 6 presents the estimates of QALY and health care (NHS and PSS) costs impacts used 
to populate the toolkit 
 
 
Endpoint 
 
Health care cost (£) QALY loss 
All-cause mortality 
 
0 8.4 1  
CHD incidence 
 
31,000 0.93 
Chronic bronchitis 
 
15,443 0.70 
Term birth low birth weight 
 
2,374 N.A. 
Pre-term birth (PTB) 
 
24,071 1.26 
Children asthma prevalence 2,439 0.87 
 
 
1 It should be reminded that this QALY impact pertains to each attributable death, which is simply a 
statistical number obtained by multiplying background mortality rate by the risk estimate of excess death 
DQGGRHVQRWUHIOHFWWKH³WUXH´QXPEHUVRIGHDWKRFFXUULQJLQWKHSRSXODWLRQ,QRWKHUZRUGVit should not 
be not interpreted as³each person dying prematurely will lose on average 8.4 QALY´. 
 
 
Table 6: Health care costs and QALY impacts associated with each adverse health endpoint. 
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4. Toolkit customisation and input data update 
 
 
All the explanations pertaining to the use of the toolkit including input data to enter (such as 
money value for a QALY, target population size, emission reduction) is provided in the 
spread-VKHHW³5($'-0(´RIWKHtoolkit. 
 
This section aims to underline possibilities to customize the toolkit, so that it matches more 
closely with the end-XVHU¶VQHHGVDQG/or to update the toolkit input data so that it remains up-
to date with the latest epidemiological evidence and guidelines. 
 
All results provided in Table 3, 4 and 6 that were used to populate the toolkit are accessible in 
the spreadsheet ³XVLQJHPLVVLRQVDQG+,$UHVXOWV´ Therefore, instead of providing an overall 
damage cost result, a strength of this toolkit is to allow the end-user to understand the 
contribution of each health endpoint to the final result and if desired, to adjust all or a 
selection of input data. 
 
Note that adjustments can only be done is the spread-VKHHW³XVLQJHPLVVLRQVDQG+,$
UHVXOWV´ 
 
4.1. Alter selection of health endpoints constituting ³ORZ´DQG³KLJK´UDQJHs  
 
The selection of endpoints that constitutes the ³ORZ´DQG³KLJK´UDQJHRILPSDFWVGHVFULEHGLQ
Table 3) may be modified by adjusting Table 2 of the spread-sheet (Cells O12 to T17). 
 
4.2. Incorporate new pieces of epidemiological evidence / change in guidelines  
 
As further epidemiological results become available, the end-user may easily incorporate the 
latest evidence for a particular endpoint, by multiplying estimates of numbers of averted 
cases of this endpoint /tonne /year/ 100,000 individuals (all ages) provided in cells E9 to G18 
with an adjustment factor AF that derives from the formula for health impact function provided 
in equation (1): 
 
 
AFEndpoint = (New REǻ[new ǻPǻ[new)   - 1) / (Current REǻ[ ǻPǻ[ - 1)    (2) 
 
:KHUH³Current REǻ[´  and ³ǻ[´are defined in Table 1 DQG³ǻm´ represents the population-
weighted change in concentration modelled for the Leeds-Bradford LEZ scenario used to 
populate the toolkit i.e: ǻP = 0.5 for PM2.5 and 2.2 for NO2  (see Table 3 with Leeds pop-weight = 
83%; Bradford pop-weight = 17%). 
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For instance if, in the future, additional evidence were to suggest that the mean effect size for 
the excess risk of mortality for PM is 1.07 per 10 ȝJP3 as opposed to the currently used 
value of 1.06 per 10 ug/m3 (see Table 4), then: 
AFDeath = (1.07 (0.5/10)   - 1) / (1.06(0.5/10)  - 1)  = 1.16 and  
Updated mean number of deaths /tonne /100,000 individuals = 0.19 * 1.16 = 0.22  
 
Alternatively, if new evidence were to suggest an effect size of 1.07 per 5 ȝJP3 : 
AFDeath = (1.07 (0.5/5)   - 1) / 1.06(0.5/10)  - 1)  = 2.33 and updated mean number of deaths /tonne 
/100,000 individuals = 0.19 * 2.33 = 0.44 
 
Similarly, as mentioned in section 2.2., there is currently great uncertainty with regards to the 
overlap in effects between PM and NO2. Currently, in line with current recommendations 
(COMEAP, 2015), the risk estimates linking NO2 exposure with all-cause of death and low 
birth weight are reduced by 1/6th. However, if the guidelines were to change, the AFOverlap to 
apply to the estimates of numbers of averted cases of all-cause of death and low birth weight 
/ tonnes of NO2 reduction /year/ 100,000 provided in cells E9 to G18 would be: 
 
 
AFOverlap = (REǻ[   (1 - % reduction new) ± 1) / (REǻ[ (1 ± 1/6) - 1)   
 
 
4.3. Enter estimates from a full impact pathway approach 
 
Finally, as mentioned in section 1.2, for greater accuracy when assessing air quality 
measures outside of West Yorkshire, area-specific estimates of avoided cases of adverse 
health endpoints obtained via the ³full impact pathway approach´ (i.e. by linking changes in 
emissions to change in concentrations and associated health effects) may be entered as 
input data of the toolkit (Cells E9 to G18 of in spread-VKHHW ³XVLQJ HPLVVLRQV DQG +,$
UHVXOWV´ 
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